Quick prioritization of Cochrane reviews on benign conditions of the prostate

Abstract

AbstractIntroductionBenign conditions of the prostate include benign prostatic enlargement and prostatitis, which constitute an important cause of morbidity in men.ObjectiveWe aimed to generate a list of priority topics of interest to our external stakeholders within our editorial scope.MethodsFollowing Cochrane's guidance, we developed a tiered approach for consulting internal and external stakeholders, including members from Urological societies. First, we analyzed our portfolio, including different impact measurements, to assess the need for updates. Then, following criteria related to the feasibility, novelty and relevance of prospective topics for evidence synthesis, we narrowed the list to a suite of titles for updates or new reviews.ResultsTwelve editors provided initial feedback as to what the priorities were for updating existing reviews and for new reviews in our portfolio. The editors identified gaps in our portfolio, mainly covering new treatments for benign prostatic hyperplasia. Then we consulted external stakeholders obtaining 30 responses from 14 countries. These stakeholders provided additional information about the relative importance of existing topics and suggested new ones. We identified that many of the latter were already covered in our portfolio, highlighting gaps in their dissemination. Finally, we narrowed down four priority topics that the editorial group will take forward and two additional topics that might need other considerations before being commissioned.ConclusionsFollowing Cochrane's guidance on priority setting, we identified topics relevant to our editors and external stakeholders by analysing our portfolio and two rounds of surveys. Moreover, we identified opportunities for disseminating existing reviews. Further evaluation is needed of the following up commissioning process for priority reviews.